The etiology of pityriasis lichenoides is unknown. One of the accepted theories admits that PL is an infl ammatory response to extrinsic antigens such as infectious agents, drugs and vaccines. In recent medical literature, only the MMR vaccine (Measles, Mumps and Rubella) was associated with the occurrence of this disease. We present a case of a male, 12 year old healthy patient who, fi ve days after Infl uenza vaccination, developed erythematous papules on the trunk, abdomen and limbs, some with adherent crusts and associated systemic symptoms. This case report is notable for describing the fi rst case of pityriasis lichenoides et varioliformis acuta associated with the vaccine against Infl uenza.
INTRODUCTION
Pityriasis lichenoides (PL) represents a group of infl ammatory cutaneous diseases with variable clinical spectrum. Mucha was the fi rst one to separate the acute form of PL from the chronic form of this disease in 1916. Later, in 1966, Degos et al described an ulceronecrotic variant of acute PL associated with fever, which was named Febrile Ulceronecrotic MuchaHabermann disease. 1 Currently three subtypes of this spectral disease are recognized: pityriasis lichenoides et varioliformis acuta (PLEVA), pityriasis lichenoides chronica (PLC) and febrile ulceronecrotic MuchaHabermann disease. 1, 2 It is known that PL affects children and young adults, peaking in the third decade of life. 1 Men are three times more affected than women, whereas PLC is six times more common than PLEVA. 3, 4 PLEVA is clinically presented as erythematous macules smaller than 5mm, which rapidly evolve to papules with thin micaceous desquamation. Papules with a vesicopustular central point, eventually hemorrhagic adherent crust and varioliform scars are not uncommon. Residual hypochromias and hyperchromias may occur, rarely accompanied by malaise, fever, lymphadenopathies and arthritis. In PLC papules usually are asymptomatic with an indolent course of weeks to months, leaving residual hyperchromic macules. On the other hand, in febrile ulceronecrotic Mucha-Habermann disease, there is rapid progression to necrotic papules with hemorrhagic blisters, confl uent ulcers and pustules. Systemic manifestations are common. 
CASE REPORT
Male patient, 12 years old, without previous history of chickenpox. Five days after vaccination against the Infl uenza virus, he presented multiple erythematous papules on the trunk, abdomen and limbs, associated with mild pruritus. Initially with no systemic symptoms, the patient was diagnosed at a basic health service facility as having chickenpox and medication was prescribed to control symptoms. With no improvement of cutaneous symptoms, the patient was treated at the emergency care facility with fever (38.4° C), tachycardia, moderate dehydration, vomiting and prostration.
At the dermatological examination he presented 2-4mm erythematous papules, some fi nely scaly, located on limbs, trunk and abdomen. Many were purpuric, with necrotic adhered crusts and associated varioliform scars ( ) and C-reactive protein (37.5 mg/l). Serologies for Hepatitis B and C, Epstein Barr virus, Cytomegalovirus, Rubella and Toxoplasmosis were negative. Histopathological examination revealed an extensive lymphocytic infl ammatory infi ltrate invading the epidermis, with vacuolization of basal layer, associated with extravasated erythrocytes (Figures 4 and 5) . The diagnosis of PLEVA was established from the association of clinical and histopathological data.
The patient was hospitalized and prednisone 1mg/kg/day was prescribed for 10 days, erythromycin 50mg/kg/day twice a day for 7 days. He remained in observation for two days due to the associated systemic symptoms. Later, it was decided to replace macrolide with tetracycline 1g/day for 28 days, due to persistence of cutaneous lesions. After three months, the patient obtained an almost complete remission of lesions. Phototherapy was not indicated since there was improvement of symptoms.
DISCUSSION
Although PLC is the most common variant in the population in general, recent studies have demonstrated that the PLEVA is the most common presentation form in children. 3 In most cases the etiology remains unknown.
There are three accepted theories to explain the pathogenesis of PL. 1 The fi rst states that it would be an infl ammatory reaction triggered by extrinsic antigens, such as: infectious agents (HIV, cytomegalovirus, Epstein-Barr virus, parvovirus B19, Toxoplasma gondii, Mycoplasma virus and Staphylococcus); drugs (hormone therapy with estrogen-progesterone, chemotherapeutics); and vaccine (MMR -mumps, measles and rubella). 6, 7 The second hypothesis The diagnosis is established clinically and by histopathology, which varies according to the phase, acute or chronic. The most common changes include: lymphocytic infi ltrate with mixed neutrophils and histiocytes, exocytosis, parakeratosis, red blood cell extravasation and necrosis of keratinocytes with intraepidermal vesicles. 1 In immunohistochemistry the presence of CD30+ lymphoid cells and atypical lymphoid cells may occur in an unspecifi c way, but suggest the diagnosis of lymphomatoid papulosis, an important differential diagnosis of PL. 1 The differential diagnosis of chickenpox also stands out, an extremely prevalent disease, which is usually mistaken for PLEVA.
This report becomes interesting by allowing to infer the probable cause of development of PLEVA. As reported, the patient showed fi rst symptoms fi ve days after taking the vaccine against Infl uenza, composed of different strains of Myxovirus infl uenzae virus.
In recent medical literature, associations between Infl uenza vaccine and dermatological diseases are described as palmoplantar keratoderma, lichen planus, Gianotti-Crosti syndrome, erythema multiforme and pityriasis rosea. 5, 8 However, after extensive review of scientifi c literature (PubMed, Science Direct, Scielo and Lilacs), we did not fi nd reports of association between PLEVA and this vaccine. Only two cases of PL induction by vaccination stand out, both MMR (mumps, measles and rubella) cases. 5, 6 The systemic presentation of PLEVA is also rare. Symptoms like fever, adynamia, vomiting and dehydration are uncommon, being found more frequently in the ulceronecrotic variant of PL.
First-line therapy include the use of topical corticoids and calcineurin inhibitors. Several authors report success using tetracycline in the dose of 1-2g/ day (for patients over 8 years of age) and erythromycin, 1-2g/day, for two to four weeks. 1 However, some studies demonstrate that children present lower therapeutic response to the use of antibiotics than adults. Wahie et al. 9 reported a response rate of only 25% in children using erythromycin, while in adults there was preferences for minocycline with a response rate of 75%. 7 UVB phototherapy has proved more effi cient than antibiotics in children, but with high rates of recurrence. 7 As second-line therapy methotrexate, PUVA, dapsone, cyclosporine, prednisone and retinoids stand out. 1, 10 We emphasize the necessity of in-depth instruction of medical professionals regarding the recognition of pityriasis lichenoides. It is frequently mistaken for chickenpox, especially when it involves the pediatric age bracket and manifests itself with polymorphic lesions. ❑ 
